COMPANY
MapLight Therapeutics
MapLight’s preclinical pipeline includes compounds for the potential treatment of Parkinson’s disease, hyperactivity, and impulsivity. From company website Source · Oct 13, 2026
Since the raise (Aug 13, 2026): 3 of 3 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Director, Safety Scientist, Pharmacovigilance | Remote | Oct 21, 2026 | Oct 22, 2026 |
| Director, Pharmacovigilance Operations | Remote | Oct 16, 2026 | Oct 17, 2026 |
| Senior Clinical Research Associate (CRA) - Florida | Florida Region | Sep 10, 2026 | Oct 5, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (3 open jobs at last check). source ↗
- Raise Private placement: $150M (total, as published), announced Aug 13, 2026. Source: SEC filing. source ↗
- Trial start Phase 2: A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia source ↗
- Trial start Phase 2: An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis source ↗
- Raise IPO: $296.3M (total, as published), announced Oct 29, 2025. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 2: A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis source ↗
- Raise Private equity round — Series D: $372.5M (total, as published), announced Jul 28, 2025. Source: company's own press page. source ↗
- Trial start Phase 2: A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia source ↗
- Trial start Phase 2: ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) source ↗
- Trial start Phase 2: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) source ↗
Upcoming milestones
- 2027-11 (ESTIMATED) · Phase 2 · ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) · NCT05889273
- 2027-12 (ESTIMATED) · Phase 2 · A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis · NCT06887192
- 2029-03 (ESTIMATED) · Phase 2 · An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis · NCT07459660
- 2030-02 (ESTIMATED) · Phase 2 · A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia · NCT07459647
Open jobs 3
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Director, Safety Scientist, Pharmacovigilance | Remote | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| Director, Pharmacovigilance Operations | Remote | Oct 16, 2026 | Oct 17, 2026 | Not stated |
| Senior Clinical Research Associate (CRA) - Florida | Florida Region | Sep 10, 2026 | Oct 5, 2026 | Senior |
Funding
- Private placement: $150M (total, as published), announced Aug 13, 2026. Source: SEC filing. source ↗
- IPO: $296.3M (total, as published), announced Oct 29, 2025. Source: company release on GlobeNewswire. source ↗
- Private equity round — Series D: $372.5M (total, as published), announced Jul 28, 2025. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 6
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06887192 | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | Phase 2 | Recruiting | Aug 15, 2025 | 2027-12 (estimated) |
| NCT07459647 | A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia | Phase 2 | Recruiting | Mar 31, 2026 | 2030-02 (estimated) |
| NCT07459660 | An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis | Phase 2 | Enrolling by invitation | Mar 25, 2026 | 2029-03 (estimated) |
| NCT05889273 | ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) | Phase 2 | Active, not recruiting | Jun 1, 2023 | 2027-11 (estimated) |
| NCT07038876 | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia | Phase 2 | Completed | Jun 27, 2025 | Jun 4, 2026 (actual) |
| NCT05081245 | ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) | Phase 2 | Completed | Sep 13, 2022 | Mar 10, 2026 (actual) |
Raises and investors new
- Raise Private raise (SEC Form D): $188.2M sold of $372.4M offered; issuer “MapLight Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗
Connect
See your connections at MapLight Therapeutics on LinkedIn (search by name, results not checked)